Effect of Teriparatide, Alendronate, Zoledronic Acid, and combined effect of Teriparatide and Alendronate treatment of primary osteoporosis
Phase 2
- Conditions
- Osteoporosis.Idiopathic osteoporosis
- Registration Number
- IRCT201605169014N99
- Lead Sponsor
- Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
primary osteoporosis; T-score less than -2.5 in the lumbar spine or femoral neck; female; age of 44 to 99 years.
Exclusion criteria: secondary osteoporosis; using prednisolone more than 3 months; rheumatologic disease; malignancy; hypothyroidism; renal failure; history of surgery of parathyroid gland.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessing the bone density. Timepoint: before treatment and one year later. Method of measurement: using Dual X-ray Absorptiometry.
- Secondary Outcome Measures
Name Time Method Assessing the bone density. Timepoint: before treatment and one year later. Method of measurement: using T-score.